Pharma: Clinic Roundup
• Sanofi SA, of Paris, said vaccine division Sanofi Pasteur reported Phase III data from a pediatric study of quadrivalent influenza vaccine (QIV) in children 6 months through 8 years of age, with results supporting results in prior studies in adults.